Latest filing published 08 Jun 2022 for Cortexyme, Inc., €18k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Caryn Gordon McDowell: trading record in brief
Caryn Gordon McDowell, listed as senior executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Cytokinetics Inc, Revance Therapeutics, Inc. and IRulya Therapeutics Inc. Between 28 February 2017 and 6 June 2022, the trades on record add up to 98 filings.
No open-market purchase appears, only 68 sales worth €516k. Other entries cover 9 share grants and 18 option exercises. 2022 to date brings no purchases and 1 sale.
The latest filing, published on 8 June 2022, reports an open-market sale of €29k in IRulya Therapeutics Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Caryn Gordon McDowell
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,700 shares@ US$2.8632100.0% of flowCommon StockSEC:0001209191-22-035014:0
- 140,000 shares0Common StockSEC:0001209191-22-016441:0
2 of 2 declarations
